Skip to main content

Advertisement

SpringerLink
Log in

Renin inhibitors: Optimal strategy for renal protection

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Diabetic nephropathy and hypertension are the major causes of chronic kidney disease. The renin system plays a key role in the control of blood pressure (BP), as well as in the regulation of renal and adrenal function. Chronic activation of the renin system can lead to organ damage, particularly renal damage; increasing evidence indicates that suppression of the renin system can provide renal protection. Despite the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), the renin system is not completely suppressed. The direct renin inhibitors (DRIs) provide suppression of the entire renin system at the rate-limiting step. Studies in humans with early DRIs indicated potential renoprotective effects, but these agents failed in clinical development due to poor oral bioavailability. Aliskiren is a new orally active DRI with proven BP-lowering effects. Animal studies indicate that aliskiren may provide renal protection, and data from human studies are anticipated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. National Kidney Foundation: Kidney disease. Available at: http://www.kidney.org/kidneyDisease/. Accessed November 16, 2006.

  2. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.

  3. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.

    Article  PubMed  CAS  Google Scholar 

  4. Neal B, MacMahon S, Chapman N, et al.: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000, 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  5. Strippoli GF, Bonifati C, Craig M, et al.: Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, (4):CD006257.

  6. Carey RM, Siragy HM: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261–271.

    Article  PubMed  CAS  Google Scholar 

  7. Kaschina E, Unger T: Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003, 12:70–88.

    Article  PubMed  CAS  Google Scholar 

  8. Brewster UC, Setaro JF, Perazella MA: The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003, 326:15–24.

    Article  PubMed  Google Scholar 

  9. Cooper ME: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004, 17:16S–20S.

    Article  PubMed  CAS  Google Scholar 

  10. Hilgers KF, Mann JF: ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:1100–1108.

    PubMed  CAS  Google Scholar 

  11. Schmieder RE: Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005, 18:720–730.

    Article  PubMed  CAS  Google Scholar 

  12. Mezzano S, Droguett A, Burgos ME, et al.: Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 2003, 86:S64–S70.

    Article  PubMed  CAS  Google Scholar 

  13. Navar LG, Harrison-Bernard LM, Nishiyama A, Kobori H: Regulation of intrarenal angiotensin II in hypertension. Hypertension 2002, 39:316–322.

    Article  PubMed  CAS  Google Scholar 

  14. Hollenberg NK, Price DA, Fisher ND, et al.: Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003, 63:172–178.

    Article  PubMed  CAS  Google Scholar 

  15. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW: The renin angiotensin system and cardiovascular risk. Lancet 2007, 369:1208–1219.

    Article  PubMed  CAS  Google Scholar 

  16. Wolf G: Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Nephrologie 1998, 19:451–456.

    PubMed  CAS  Google Scholar 

  17. Schmieder RE: The potential role of prorenin in diabetic nephropathy. J Hypertens 2007, 25:1323–1326.

    Article  PubMed  CAS  Google Scholar 

  18. Reudelhuber TL: The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005, 46:1261–1262.

    Article  PubMed  CAS  Google Scholar 

  19. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857–1863.

    Article  Google Scholar 

  20. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  21. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851–860.

    Article  PubMed  CAS  Google Scholar 

  22. Pohl MA, Blumenthal S, Cordonnier DJ, et al.: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027–3037.

    Article  PubMed  CAS  Google Scholar 

  23. Weber MA, Giles TD: Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006, 7:45–54.

    Article  PubMed  Google Scholar 

  24. Rossing K, Schjoedt KJ, Jensen BR, et al.: Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005, 68:1190–1198.

    Article  PubMed  CAS  Google Scholar 

  25. Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angioten sin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124.

    Article  PubMed  CAS  Google Scholar 

  26. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.

    Article  PubMed  CAS  Google Scholar 

  27. Schmieder RE, Klingbeil AU, Fleischmann EH, et al.: Additional antiproteinuric effect of ultrahigh-dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005, 16:3038–3045.

    Article  PubMed  CAS  Google Scholar 

  28. Stanton A: Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003, 3:389–394.

    Article  PubMed  CAS  Google Scholar 

  29. Wood JM, Maibaum J, Rahuel J, et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003, 308:698–705.

    Article  PubMed  CAS  Google Scholar 

  30. Pool J, Gradman A, Kolloch R, et al.: Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. Eur Heart J 2006, 27:119.

    Google Scholar 

  31. Kilo C, Taylor A, Tschoepe D, et al.: Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur Heart J 2006, 27:118–119.

    Google Scholar 

  32. Azizi M, Menard J, Bissery A, et al.: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004, 15:3126–3133.

    Article  PubMed  Google Scholar 

  33. Nguyen G, Delarue F, Burckle C, et al.: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002, 109:1417–1427.

    Article  PubMed  CAS  Google Scholar 

  34. Azizi M, Webb R, Nussberger J, Hollenberg NK: Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006, 24:243–256.

    Article  PubMed  CAS  Google Scholar 

  35. Webb DJ, Manhem PJ, Ball SG, et al.: Clinical and biochemical effects of the renin inhibitor H142 in humans. J Cardiovasc Pharmacol 1987, 10:S69–74.

    Article  PubMed  CAS  Google Scholar 

  36. Zusman RM, Hui KY, Nussberger J, et al.: R-PEP-27, a potent renin inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. Am J Hypertens 1994, 7:295–301.

    PubMed  CAS  Google Scholar 

  37. Menard J, Boger RS, Moyse DM, et al.: Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 1995, 91:330–338.

    PubMed  CAS  Google Scholar 

  38. Azizi M, Guyene TT, Chatellier G, Menard J: Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1994, 12:419–427.

    Article  PubMed  CAS  Google Scholar 

  39. Neutel JM, Luther RR, Boger RS, Weber MA: Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J 1991, 122:1094–1100.

    Article  PubMed  CAS  Google Scholar 

  40. Oh B-H, Chung J, Khan M, et al.: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in patients with hypertension. J Am Coll Cardiol 2006, 47:370A.

    Article  Google Scholar 

  41. Gradman AH, Schmieder RE, Lins RL, et al.: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005, 111:1012–1018.

    Article  PubMed  CAS  Google Scholar 

  42. Weir MR, Bush C, Zhang J, et al.: Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. Eur Heart J 2006, 27:299.

    Google Scholar 

  43. Strasser RH, Puig JG, Farsang C, et al.: The oral renin inhibitor aliskiren has comparable safety and efficacy to lisinopril in patients with severe hypertension. J Hypertens 2006, 24:99–100.

    Google Scholar 

  44. Uresin Y, Taylor A, Kilo C, et al.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J Hypertens 2006, 24:S82.

    Google Scholar 

  45. Villamil A, Chrysant S, Calhoun D, et al.: The novel oral renin inhibitor aliskiren provides effective blood pressure control in patients with hypertension when used alone or in combination with hydrochlorothiazide. J Clin Hypertens 2006, 8:A100.

    Google Scholar 

  46. Munger MA, Drummond W, Essop MR, et al.: Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur Heart J 2006, 27:117.

    Google Scholar 

  47. Mitchell J, Oh B, Herron J, et al.: Once-daily aliskiren provides effective, smooth 24-hour blood pressure control in patients with hypertension. J Clin Hypertens 2006, 8:A93.

    Article  Google Scholar 

  48. Herron J, Mitchell J, Oh B, et al.: The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens 2006, 8:A86–87.

    Article  Google Scholar 

  49. Sica D, Gradman A, Lederballe O, et al.: Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006, 27:121.

    Google Scholar 

  50. Fisher ND, Hollenberg N: Renal vascular responses to renin inhibition with zankiren in men. Clin Pharmacol Ther 1995, 57:342–348.

    Article  PubMed  CAS  Google Scholar 

  51. van Paassen P, de Zeeuw D, Navis G, de Jong PE: Renal and systemic effects of continued treatment with renin inhibtor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant 2000, 15:637–643.

    Article  PubMed  Google Scholar 

  52. Pilz B, Shagdarsuren E, Wellner M, et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005, 46:569–576.

    Article  PubMed  CAS  Google Scholar 

  53. Fiebeler A, Shagdarsuren E, Pilz B, et al.: Low-dose renin inhibitor and AT1 receptor blocker ameliorate angiotensin II_induced end-organ damage despite persistence of hypertension. Results presented at Renal Week. Philadelphia, PA; November 8–13, 2005.

  54. Feldman DL, Jin L, Miserindino-Moltini R, et al.: Aliskiren, a human renin inhibitor induces persistent renoprotection comparable to ACE inhibition in double transgenic rats (dTGR). Am J Hypertens 2005, 8:230A.

    Article  Google Scholar 

  55. Feldman DL, Jin L, Miserindino-Moltini R, et al.: The renin inhibitor aliskiren ameliorates hypertensive diabetic nephropathy in transgenic (nRen-2)27 (Ren-2) rats. Results presented at Renal Week. Philadelphia, PA; November 8–13, 2005.

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Friedrich-Alexander-University Erlangen-Nürnberg, Krankenhausstraße 12, 91054, Frlangen, Germany

    Roland E. Schmieder

Authors
  1. Roland E. Schmieder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roland E. Schmieder.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmieder, R.E. Renin inhibitors: Optimal strategy for renal protection. Current Science Inc 9, 415–421 (2007). https://doi.org/10.1007/s11906-007-0076-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0076-5

Keywords

Search

Navigation